Moderna (MRNA) vs Repligen (RGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Moderna (MRNA) has outperformed Repligen (RGEN) over the past year, gaining 722.1% versus a gain of 0.8%. Over five years, MRNA leads with a -40.8% price change compared with -42.7% for RGEN. Moderna is the larger company by market cap ($78.90 billion vs $10.47 billion), about 7.5 times the size, while Repligen is growing revenue faster (+16.4% vs -39.9%).
Repligen converts more of its revenue into profit, with a net margin of 6.6% versus -145.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRNA | RGEN |
|---|---|---|
| Share price | $195.00 | $163.81 |
| Market cap | $78.90B | $10.47B |
| 1-day change | -2.17% | -3.81% |
| YTD return | +561.24% | -0.03% |
| 1-year return | +722.09% | +0.80% |
| 5-year return | -40.84% | -42.73% |
| Forward P/E | — | 61.77 |
| EPS (TTM) | $-7.04 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.94B | $738.26M |
| Revenue growth (YoY) | -39.93% | +16.36% |
| Net income (latest FY) | $-2.82B | $48.89M |
| Gross margin | 55.35% | 52.32% |
| Operating margin | -158.13% | 7.47% |
| Net margin | -145.16% | 6.62% |
| 52-week high | $280.80 | $198.87 |
| 52-week low | $23.55 | $100.99 |
| Distance from 52-week high | -30.56% | -17.63% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -15.22% | +24.05% |
| Average volume | 16.52M | 1.17M |
| Shares outstanding | 404.62M | 63.92M |
| Employees | 4,700 | 2,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Moderna is about 7.5 times larger than Repligen by market value ($78.90B vs $10.47B).
- MRNA has outperformed RGEN by 721.3 percentage points over the past year.
- Repligen is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -145.2 cents for Moderna.
- Repligen grew revenue faster in its latest fiscal year (+16.36% vs -39.93%).
About Moderna
MRNA stock →Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 4,700 employees
About Repligen
RGEN stock →Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,000 employees
MRNA vs RGEN FAQ
Which is bigger, Moderna or Repligen?
Moderna (MRNA) is larger, with a market capitalization of $78.90B compared with $10.47B for Repligen (RGEN).
Which stock has performed better over the past year, MRNA or RGEN?
MRNA returned +722.09% over the past 12 months, compared with +0.80% for RGEN (price return, excluding dividends). Past performance does not predict future results.
Are Moderna and Repligen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.